Morphine effects on HTLV-I infection in the presence or absence of concurrent HIV-1 infection

DNA and Cell Biology

Volumn 18, Issue 4, 1999, Pages 285-291

  Nyland, Susan B ^a   Specter, Steven ^a   Ugen, Kenneth E ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2; MORPHINE; NALOXONE; NARCOTIC ANTAGONIST; VIRUS ANTIGEN;

ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG ABUSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; NONHUMAN; ONCOVIRINAE; PRIORITY JOURNAL; RETROVIRUS; VIRUS CELL INTERACTION;

CELL LINE; CYTOPATHOGENIC EFFECT, VIRAL; GENE PRODUCTS, GAG; HIV-1; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; INTERLEUKIN-2; MORPHINE; RETROVIRIDAE PROTEINS, ONCOGENIC;

HTLV; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 1; ONCOVIRINAE; UNIDENTIFIED RETROVIRUS;

EID: 0007409318     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454999315349     Document Type: Article

References (34)

1. BARCOVA, M., KACANI, L., SPETH, C., and DIERICH, M.P (1998). gp41 envelope protein of human immunodeficiency virus induces interleukin (IL)-10 in monocytes, but not in B, T, or NK cells, leading to reduced IL-2 and interferon-gamma production. J. Infect. Dis. 177, 905-913.
2. BARTHOLOMEW, C., BLATTNER, W., and CLEGHORN, F. (1987). Progression to AIDS in homosexual men co-infected with HIV and HTLV-I in Trinidad. Lancet 19, 1469.
3. BEILKE, M.A., GREENSPAN, D.L., and IM PEY, A. (1994). Laboratory study of HIV-1 and HTLV-I/II coinfection. J. Med. Virol. 44, 132-143.
4. BEILKE, M.A., SHANKER, J., and VINSON, D.G. (1998). HTLV-I and HTLV-II virus expression increase with HIV-1 coinfection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17, 391-397.
5. CDC. (1997). CDC AIDS Information. Centers for Disease Control and Prevention, Atlanta (www.cdc.gov document 260210.html).
6. CLEGHORN, F.R., and BLATTNER, W.A. (1992). Does human T cell lymphotropic virus type I and human immunodeficiency virus type 1 coinfection accelerate acquired immune deificiency syndrome? the jury is still out. Arch. Intern. Med. 152, 1372-1373.
7. DONAHOE, R.M., and VLAHOV, D. (1998). Opiates as potential co-factors in progression of HIV-1 infections to AIDS. J. Neuroimmunol. 83, 77-87.
8. FLEMING, P.L., WARD, J.W., KARON, J.M., HANSON, D.L., and DECOCK, K.M. (1998). Declines in AIDS incidence and deaths in the USA: a signal change in the epidemic. AIDS 12A, S55-S61.
9. GESSAIN, A. (1996). Epidemiology of HTLV-I and Associated Diseases. (Wiley and Sons, New York) pp. 33-65.
10. GOOD, L., MAGGIRWAR, S.B., and SUN, S.C. (1996). Activation of the IL-2 gene promoter by HTLV-I Tax involves induction of NF-AT complexes bound to the CD28-responsive element. EMBO J. 15, 3744-3750.
11. HALL, W.W., KAPLAN, M.H., SALAHUDDIN, S.Z., OYAIZE, N., GURGO, C., CORONESI, M., NAGASHIMA, K., and GALLO, R.C. (1990). Concomitant infections with human T-cell leukemia viruses (HTLV) and human immunodeficiency virus (HIV): identification of HTLV-II infection in intravenous drug abusers (IVDAs). In Human Retrovirology-HTLV. W.A. Blattner, ed. (Raven Press, New York) pp. 115-127.
12. HARRINGTON, W.J.J., UCAR, A., GILL, P., SNODGRASS, S., SHEREMATA, W., CABRAL, L., RABIN, M., BYRNE, G.E., JR., BERGER, J., VOIGHT, W., KEMPER, R., MILLER, G., WHITCOMB, C.C., GREENBERG, A., BYRNES, J.J., and POIESZ, B. (1995). Clinical spectrum of HTLV-I in south Florida. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8, 466-473.
13. HARRISON, L.H., VAZ, B., TAVEIRA, D.M., QUINN, T.C., GIBBS, C.J., DESOUZA, S.H., MCARTHUR, J.C., and SCHECHTER, M. (1997). Myelopathy among Brazilians coinfected with human T-cell lymphotropic virus type I and HIV. Neurology 48, 13-18.
14. + lymphocytes is highly cytolytic for both cells. J. Virol. 69, 6925-6931.
15. JOHNSON, V.A., and BYINGTON, R.E. (1990). Quantitative assays for virus infectivity. In Techniques in HIV Research. A. Aldovini and B.D. Walker, eds. (Stockton Press, New York) pp. 71-76.
16. KAPLAN, M.H., SADICK, N.S., MCNUTT, N.S., TALMOR, M., CORONESI, M., and HALL, W.W. (1993). Acquired ichthyosis in concomitant HIV-1 and HTLV-II infection: a new association with intravenous drug abuse. J. Am. Acad. Dermatol. 29, 701-708.
17. KLIMAS, N.G., PAGE, J.B., PATARCA, R., CHITWOOD, D., MORGAN, R., and FLETCHER, M.A. (1993). Effects of retroviral infections on immune function in African-American intravenous drug users. AIDS 7, 331-335.
18. KORANT, B.D., STRACK, P., FREY, M.W., and RIZZO, C.J. (1998). A cellular anti-apoptosis protein is cleaved by the HIV-1 protease. Adv. Exp. Med. Biol. 436, 27-29.
19. LAFRERE, H.H., COUROUSE, A.M., and MARIOTTI, M. (1990). Rapid progression to AIDS in dual HIV-I/HTLV-I infection. Lancet 336, 509.
20. MADDEN, J.J., WHALEY, W.L., and KETELSEN, D. (1998). Opiate binding sites in the cellular immune system: expression and regulation. J. Neuroimmunol. 83, 57-62.
21. MELLON, R.D., and BAYER, B.M. (1998). Evidence for central opioid receptors in the immunomodulatory effects of morphine: review of potential mechanism(s) of action. J. Neuroimmunol. 83, 19-28.
22. MURPHY, E.L. (1996). The Epidemiology of HTLV-I: Modes of Transmission and Their Relation to Patterns of Seroprevalence. In Human Retrovirology-HTLV. W.A. Blattner, ed. (Raven Press, New York) pp. 295-305.
23. NICOT, C., ASTIER-GIN, T., and GUILLEMAIN, B. (1997). Activation of Bcl-2 expression in human endothelial cells chronically expressing the human T-cell lymphotropic virus type I. Virology 236, 47-53.
24. NYLAND, S.B., SPECTER, S., SIN, J.I., and UGEN, K.E. (1998). Opiate effects on in vitro human retroviral infection. Adv. Exp. Med. Biol. 437, 91-100.
25. PETERSON, P.K., MOLITOR, T.W., and CHAO, C.C. (1998). The opioid-cytokine connection. J. Neuroimmunol. 83, 63-69.
26. SCHECHTER, M., MOULTON, L.H., and HARRISON, L.H. (1997). HIV viral load and CD4+ lymphocyte counts in subjects coinfected with HTLV-I and HIV-1. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol 15, 308-311.
27. SCHWEBKE, J., CALSYN, D., and SHRIVER, K. (1994). Prevalence and epidemiological correlates of human T cell lymphotropic virus infection among intravenous drug users. J. Infect. Dis. 169, 962-967.
28. SHARP, B.M., ROY, S., and BIDLACK, J.M. (1998). Evidence for opioid receptors on cells involved in host defense and the immune system. J. Neuroimmunol. 83, 45-56.
29. SHI, Y., WANG, R., SHARMA, A., GAO, C., COLLINS, M., PENN, L., and MILLS, G.B. (1997). Dissociation of cytokine signals for proliferation and apoptosis. J. Immunol. 159, 5318-5328.
30. SHIBASAKI, F., KONDO, E., AKAGI, T., and MCKEON F. (1997). Suppression of signaling through transcription factor NF-AT by interactions between calcineurin and Bcl-2. Nature 386, 728-731.
31. TAKE, H., UMEMOTO, M., KUSHUARA, K., and KURAYA, K. (1993). Transmission routes of HTLV-I: an analysis of 66 families. Jpn. J. Cancer Res. 84, 1265-1267.
32. WANG, H., NISHANIAN, P., and FAHEY, J.L. (1995). Characterization of immune suppression by a synthetic HIV gp31 peptide. Cell. Immunol. 161, 236-243.
33. WIKTOR, S.Z., CANNON, R.O., and ATKINSON, W.L. (1992). Infection with human T lymphotropic virus types I and II in sexually transmitted disease clinics in Baltimore and New Orleans. J. Infect. Dis. 165, 920-924.
34. YU, Y., ZHANG, L., YIN, X., SUN, H., UHL, G.R., and WANG, J.B. (1997). Mu opioid receptor phosphorylation, desensitization, and ligand efficacy. J. Biol. Chem. 272, 28869-28874.